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We describe the design, synthesis and in vitro evaluation of a multimodal and multimeric contrast agent. The agent consists of three macrocyclic Gd(III) chelates conjugated to a fluorophore and possesses high relaxivity, water solubility, and is nontoxic. The modular synthesis is amenable for the incorporation of a variety of fluorophores to generate molecular constructs for a number of applications.
The advent of a number of highly sensitive, tomographic imaging modalities has enabled scientists and clinicians to acquire in vivo images of animals without the need for sacrifice. [1] [2] [3] Each modality possesses unique strengths where the combination of two or more imaging modalities continues to impact our understanding of complex biological processes and drug development. 4 Techniques for in vivo imaging include positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance (MR). 5 Although each modality provides high resolution in vivo tomographic information, MR imaging is well suited for longitudinal assessment of in vivo processes because it does not require ionizing radiation (CT) or the use of radioactive tracers (PET and SPECT). For example, MRI has been used to fate map cells in developing embryos where the descendants of individual precursors were labeled with a stable, nontoxic, lineage tracer (MRI contrast agent) which allowed researchers to determine the cell location and migration responsible for embryonic development. 6 However, the low probe sensitivity and limited spatial resolution of MRI preclude the observation of molecular events. Optical imaging is a modality that provides high resolution and probe sensitivity to detect subcellular localization and molecular interactions. The integration of optical and MR imaging is therefore an appealing approach to facilitate applications such as fate mapping transplanted stem cells, 7-9 early detection of cancer, 10 tracking gene expression, 11 and importantly, histological validation of MR signal.
There have been an increasing number of reports of multimodal MR-optical contrast agents using a wide variety of nanoconjugates and fluorophores. 12, 13 However, the intrinsic variability of nanoparticles can be an obstacle for some applications. In order to address this issue researchers have developed small molecule MRoptical contrast agents consisting of a Gd(III)-based chelate conjugated to near-IR dyes, 14 rhodamine, 15, 16 cyanine7, 17 and fluorescein. 17 Typically, these agents have been shown to have relatively low relaxivities and limited water solubility. Further, conjugating agents to dendrimer scaffolds has been shown to increase relaxivity, but the resultant agents were polydisperse and difficult to characterize. 18, 19 To overcome these limitations we report the synthesis, characterization and in vitro evaluation of a high relaxivity, multimeric and multimodal MR-optical contrast agent. The design is based upon our previously reported agent where three Gd(III) chelates are conjugated to a phenolic core. 20 We modified this design to allow conjugation of fluorescein to generate a highly watersoluble MR-optical agent which labels cells with high efficiency and generates significant MR contrast enhancement at clinical (1.4 T) and research (7 T) magnetic field strengths. To facilitate conjugation of 2 to fluorescein isothiocyanate, an amine-functionalized linker was introduced onto the phenolic core of the complex (See S1-3 ESI for further details). 1 was synthesized via the direct reaction of complex 2 with commercially available fluorescein isothiocyanate in water at pH 9.0 using potassium carbonate (Scheme 1). The reaction was performed in the dark due to the photo-instability of fluorescein.
The relaxivity of 1 and 2 were determined to be 17.0 ± 0. The complexes were further characterized by quantum yield and octanol-water partition coefficients (logP) measurements. The quantum yield of 1 was determined to be 0.56. The logP values of 1 and 2 were -2.0 and -1.9 respectively. These negative log P values are characteristic of high water solubility, indicating that conjugation of fluorescein to the contrast agent scaffold did not significantly impact solubility. As a result, incubation concentrations for in vitro studies can be made in the mM range which is important for maximizing intracellular agent concentration. Efficient cell penetration is crucial for the use of imaging probes to investigate biological mechanisms such as fate mapping cells. Cellular localization of 1 was determined using confocal laser scanning microscopy where micrographs showed intracellular accumulation of the probe (Figure 1 Cellular uptake of Gd(III) was investigated by incubating HeLa, B16-F10, or MDA-MB-231-mcherry cells with concentrations of 1 ranging from 27 to 260 µM (Figure 2 ). Cells were washed and pelleted prior to analysis to reduce non-specific binding. The cell lines were chosen to address variability in labeling arising from differences in tissue of origin (cervix, breast, and skin), species of origin (human and mouse), cell size (12-20 µm diameter), 22, 23 and cell growth rate (20-38 hr doubling times). [24] [25] [26] Cell uptake increased with cell volume with the highest labeling achieved in HeLa cells In all cell lines, uptake reached a plateau indicating that cells were saturated with probe.
Error bars represent ± standard deviation the mean of triplicate experiments.
To demonstrate that cell labeling of 1 is sufficient to produce T 1 -weighted contrast enhancement of cell populations, MR images of cell pellets were acquired at 7 T at cell densities that approximate tumor densities in vivo (Figure 3) . HeLa cells were incubated with 250 µM equalized Gd(III) of 1, 2, or ProHance® (the concentration of ProHance® is 3x higher than 1 or 2). The most significant contrast enhancement was observed in cells labeled with 1 with a 64% reduction in T 1 compared to untreated cells, followed by ProHance® (20% reduction in T 1 ), and 2 (8% reduction in T 1 ). In conclusion, we have developed a new multimeric and multimodal contrast agent that contains three Gd(III) chelates conjugated to a flurophore. The agent has high relaxivity at both low (1.4 T) and high magnetic fields (7 T), is highly water soluble, cellpermeable, and possesses excellent cell labeling capabilities. The agent shows significantly increased labeling and image contrast at 7 T compared to clinically available ProHance®. Further, the molecular architecture described can accommodate a large variety of fluorophores to generate additional molecular constructs for enhanced multimodal imaging. This work was supported by the National Institutes of Health (NIH grant R01EB005866) and by a National Science Foundation Graduate Research Fellowship (C.C.). Imaging was performed at the
